Aiguo Zeng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aiguo Zeng has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
Lu Wang
School of Medicine, Xizang Minzu University, Xianyang, 712082, China
4 shared publicationsQiang Fu
School of Pharmacy, Health Science Center, Xi'an Jiaotong University, No 76, Yanta West Road, Shaanxi Province, Xi'an, 710061, China
4 shared publicationsXin Yang
Xi’an Jiaotong University
4 shared publicationsChanghe Wang
Shaanxi Institute for Food and Drug Control, Xi'an, China
3 shared publicationsChun Chang
School of Pharmacy, Health Science Center, Xi'an Jiaotong University, No 76, Yanta West Road, Shaanxi Province, Xi'an, 710061, China
3 shared publicationsCong Li
Xi’an Jiaotong University
3 shared publications
Latest Publications
- 10 January 2023
- Published by Royal Society of Chemistry (RSC) in New Journal of Chemistry
- Vol. 47 (8) , 4103-4112
Zeolitic-imidazolate framework (ZIF-8)-based immobilized multi-enzymes integrated with a colorimetric sensor for cholesterol assay
A catalytic system of co-immobilized enzymes (Chox&HRP@ZIF-8) with good stability and reusability based on cascade reaction was designed for the detection of cholesterol. The assay has been successfully applied to serum samples.
- 10 January 2023
- Published by Royal Society of Chemistry (RSC) in New Journal of Chemistry
- Vol. 47 (8) , 4103-4112
Zeolitic-imidazolate framework (ZIF-8)-based immobilized multi-enzymes integrated with a colorimetric sensor for cholesterol assay
A catalytic system of co-immobilized enzymes (Chox&HRP@ZIF-8) with good stability and reusability based on cascade reaction was designed for the detection of cholesterol. The assay has been successfully applied to serum samples.
- 13 September 2021
- Published by American Chemical Society (ACS) in ACS Applied Nano Materials
- Vol. 4 (9) , 9060-9067
Aqueous-Based Silica Nanoparticles as Carriers for Catalytically Active Biomacromolecules
- 13 September 2021
- Published by American Chemical Society (ACS) in ACS Applied Nano Materials
- Vol. 4 (9) , 9060-9067
Aqueous-Based Silica Nanoparticles as Carriers for Catalytically Active Biomacromolecules
- 31 October 2019
- Published by Taylor & Francis in Xenobiotica
- Vol. 50 (6) , 713-721
Comparative pharmacokinetics of verapamil and norverapamil in normal and ulcerative colitis rats after oral administration of low and high dose verapamil by UPLC-MS/MS
1. In this study, UC rat model was established by administration of 5% (w/v) dextran sulfate sodium, and the pharmacokinetics of verapamil and norverapamil were evaluated in normal and UC rats using UPLC-MS/MS after oral administration of 5 mg/kg and 50 mg/kg verapamil. 2. The peak concentration (Cmax) and the area under plasma concentration–time curves (AUC) of verapamil in UC rats after oral administration of 5 mg/kg were significantly greater (2.5 times and 2 times, respectively) than those in normal rats, but the clearance rate (Cl) was significantly lower (by 50%). For norverapamil, Cmax and AUC were significantly greater (2.8 times and 2.5 times, respectively), and Cl was significantly lower (by 45%). But, pharmacokinetic parameters of verapamil and norverapamil after oral administration of 50 mg/kg were no significant differences between UC and normal rats. 3. The better absorption and poor excretion for low-dose verapamil may be attributed to down-regulation of P-gp expression in the intestine and kidney. No significant differences of pharmacokinetic parameters for high-dose verapamil may be explained as the saturation of an efflux mechanism. 4. The findings of this study suggested that in UC patients, doses of verapamil should be decreased when low-dose verapamil was orally administrated.
- 31 October 2019
- Published by Taylor & Francis in Xenobiotica
- Vol. 50 (6) , 713-721
Comparative pharmacokinetics of verapamil and norverapamil in normal and ulcerative colitis rats after oral administration of low and high dose verapamil by UPLC-MS/MS
1. In this study, UC rat model was established by administration of 5% (w/v) dextran sulfate sodium, and the pharmacokinetics of verapamil and norverapamil were evaluated in normal and UC rats using UPLC-MS/MS after oral administration of 5 mg/kg and 50 mg/kg verapamil. 2. The peak concentration (Cmax) and the area under plasma concentration–time curves (AUC) of verapamil in UC rats after oral administration of 5 mg/kg were significantly greater (2.5 times and 2 times, respectively) than those in normal rats, but the clearance rate (Cl) was significantly lower (by 50%). For norverapamil, Cmax and AUC were significantly greater (2.8 times and 2.5 times, respectively), and Cl was significantly lower (by 45%). But, pharmacokinetic parameters of verapamil and norverapamil after oral administration of 50 mg/kg were no significant differences between UC and normal rats. 3. The better absorption and poor excretion for low-dose verapamil may be attributed to down-regulation of P-gp expression in the intestine and kidney. No significant differences of pharmacokinetic parameters for high-dose verapamil may be explained as the saturation of an efflux mechanism. 4. The findings of this study suggested that in UC patients, doses of verapamil should be decreased when low-dose verapamil was orally administrated.
- 1 July 2019
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 108 (7) , 2391-2396
Inhibiting Surface Crystallization and Improving Dissolution of Amorphous Loratadine by Dextran Sulfate Nanocoating
- 1 July 2019
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 108 (7) , 2391-2396
Inhibiting Surface Crystallization and Improving Dissolution of Amorphous Loratadine by Dextran Sulfate Nanocoating
- 21 February 2017
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 18 (7) , 2541-2550
Coamorphous Loratadine-Citric Acid System with Enhanced Physical Stability and Bioavailability
Coamorphous systems using citric acid as a small molecular excipient were studied for improving physical stability and bioavailability of loratadine, a BCS class II drug with low water solubility and high permeability. Coamorphous loratadine-citric acid systems were prepared by solvent evaporation technique and characterized by differential scanning calorimetry, X-ray powder diffraction, and Fourier transform infrared spectroscopy. Solid-state analysis proofed that coamorphous loratadine-citric acid system (1:1) was amorphous and homogeneous, had a higher Tg over amorphous loratadine, and the intermolecular hydrogen bond interactions between loratadine and citric acid exist. The solubility and dissolution of coamorphous loratadine-citric acid system (1:1) were found to be significantly greater than those of crystalline and amorphous form. The pharmacokinetic study in rats proved that coamorphous loratadine-citric acid system (1:1) could significantly improve absorption and bioavailability of loratadine. Coamorphous loratadine-citric acid system (1:1) showed excellently physical stability over a period of 3 months at 25°C under 0% RH and 25°C under 60% RH conditions. The improved stability of coamorphous loratadine-citric acid system (1:1) could be related to an elevated Tg over amorphous form and the intermolecular hydrogen bond interactions between loratadine and citric acid. These studies demonstrate that the developed coamorphous loratadine-citric acid system might be a promising oral formulation for improving solubility and bioavailability of loratadine.
- 21 February 2017
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 18 (7) , 2541-2550
Coamorphous Loratadine-Citric Acid System with Enhanced Physical Stability and Bioavailability
Coamorphous systems using citric acid as a small molecular excipient were studied for improving physical stability and bioavailability of loratadine, a BCS class II drug with low water solubility and high permeability. Coamorphous loratadine-citric acid systems were prepared by solvent evaporation technique and characterized by differential scanning calorimetry, X-ray powder diffraction, and Fourier transform infrared spectroscopy. Solid-state analysis proofed that coamorphous loratadine-citric acid system (1:1) was amorphous and homogeneous, had a higher Tg over amorphous loratadine, and the intermolecular hydrogen bond interactions between loratadine and citric acid exist. The solubility and dissolution of coamorphous loratadine-citric acid system (1:1) were found to be significantly greater than those of crystalline and amorphous form. The pharmacokinetic study in rats proved that coamorphous loratadine-citric acid system (1:1) could significantly improve absorption and bioavailability of loratadine. Coamorphous loratadine-citric acid system (1:1) showed excellently physical stability over a period of 3 months at 25°C under 0% RH and 25°C under 60% RH conditions. The improved stability of coamorphous loratadine-citric acid system (1:1) could be related to an elevated Tg over amorphous form and the intermolecular hydrogen bond interactions between loratadine and citric acid. These studies demonstrate that the developed coamorphous loratadine-citric acid system might be a promising oral formulation for improving solubility and bioavailability of loratadine.
- 29 November 2016
- Published by Royal Society of Chemistry (RSC) in CrystEngComm
- Vol. 19 (2) , 335-345
Crystallization and relaxation dynamics of amorphous loratadine under different quench-cooling temperatures
In this paper, four amorphous samples of loratadine were prepared by quench-cooling the melted drug at different temperatures. With these samples, the crystallization tendencies were tested by powder X-ray diffraction (PXRD), and non-isothermal cold crystallization kinetics was investigated by using differential scanning calorimetry (DSC) and the molecular dynamics both in super-cooled liquid and in glassy states was analyzed by using broadband dielectric spectroscopy (BDS) at a temperature range from 213 to 393 K. From the PXRD results, it was established that the four amorphous loratadine samples were apt to crystallize at a temperature below the glass transition temperature. From the DSC results, it was found that the non-isothermal crystallization mechanism of these four loratadine forms was similar. However, the fast crystallization tendency (low physical stability) was also observed for the amorphous loratadine which was obtained at a low quench-cooling temperature. The tendency was analyzed based on the BDS results which demonstrated that rapid molecular mobility could generate a low physical stability and was closely related to Johari–Goldstein relaxation. These results suggested that loratadine had a weak frustration against crystallization and its physical stability was affected by the quench-cooling temperature. This study laid a foundation for choosing the right technique to prepare the amorphous form of loratadine and improving its physical stability.
- 29 November 2016
- Published by Royal Society of Chemistry (RSC) in CrystEngComm
- Vol. 19 (2) , 335-345
Crystallization and relaxation dynamics of amorphous loratadine under different quench-cooling temperatures
In this paper, four amorphous samples of loratadine were prepared by quench-cooling the melted drug at different temperatures. With these samples, the crystallization tendencies were tested by powder X-ray diffraction (PXRD), and non-isothermal cold crystallization kinetics was investigated by using differential scanning calorimetry (DSC) and the molecular dynamics both in super-cooled liquid and in glassy states was analyzed by using broadband dielectric spectroscopy (BDS) at a temperature range from 213 to 393 K. From the PXRD results, it was established that the four amorphous loratadine samples were apt to crystallize at a temperature below the glass transition temperature. From the DSC results, it was found that the non-isothermal crystallization mechanism of these four loratadine forms was similar. However, the fast crystallization tendency (low physical stability) was also observed for the amorphous loratadine which was obtained at a low quench-cooling temperature. The tendency was analyzed based on the BDS results which demonstrated that rapid molecular mobility could generate a low physical stability and was closely related to Johari–Goldstein relaxation. These results suggested that loratadine had a weak frustration against crystallization and its physical stability was affected by the quench-cooling temperature. This study laid a foundation for choosing the right technique to prepare the amorphous form of loratadine and improving its physical stability.
- 2 September 2016
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 6 (88) , 85063-85073
A new polymorphic form and polymorphic transformation of loratadine
In this work, a new form of loratadine (Form B) was prepared from a 20% methanol and 80% water mixture and characterized by polarizing microscopy (POM), scanning electron microscopy (SEM), powder X-ray diffraction (PXRD) and differential scanning calorimetry (DSC). The dissolution, solubility and interfacial energy of Form B in water were measured and compared with those of amorphous and Form A loratadine. In addition, the solid-state transformations of loratadine solid forms were investigated by hot-stage microscopy (HSM) and DSC while the non-isothermal crystallization of amorphous loratadine was studied by DSC. It was found that Form B has a unique acicular structure and PXRD pattern, which are different from Form A. Moreover, Form B has a higher equilibrium solubility compared with Form A. The results of the solid-state transformation investigation (DSC) shows that the amorphous form was changed to the new polymorph B at 106.7 °C and Form B converted exothermally to Form A at 93.9 °C during heating. In the non-isothermal crystallization of amorphous loratadine, the crystallization rate constant (Zt) increased with the increasing heating rate and the Avrami exponent (n) was found to be about 3. Hopefully, Form B will be considered to be a promising approach to improve the loratadine solubility/dissolution rate.
- 2 September 2016
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 6 (88) , 85063-85073
A new polymorphic form and polymorphic transformation of loratadine
In this work, a new form of loratadine (Form B) was prepared from a 20% methanol and 80% water mixture and characterized by polarizing microscopy (POM), scanning electron microscopy (SEM), powder X-ray diffraction (PXRD) and differential scanning calorimetry (DSC). The dissolution, solubility and interfacial energy of Form B in water were measured and compared with those of amorphous and Form A loratadine. In addition, the solid-state transformations of loratadine solid forms were investigated by hot-stage microscopy (HSM) and DSC while the non-isothermal crystallization of amorphous loratadine was studied by DSC. It was found that Form B has a unique acicular structure and PXRD pattern, which are different from Form A. Moreover, Form B has a higher equilibrium solubility compared with Form A. The results of the solid-state transformation investigation (DSC) shows that the amorphous form was changed to the new polymorph B at 106.7 °C and Form B converted exothermally to Form A at 93.9 °C during heating. In the non-isothermal crystallization of amorphous loratadine, the crystallization rate constant (Zt) increased with the increasing heating rate and the Avrami exponent (n) was found to be about 3. Hopefully, Form B will be considered to be a promising approach to improve the loratadine solubility/dissolution rate.
- 6 December 2012
- Published by Springer Nature in Journal of Solution Chemistry
- Vol. 41 (11) , 1986-1992
Solubility, Dissolution Enthalpy and Entropy of Isoimperatorin in Ethanol + Water Solvent Systems from 288.2 to 328.2 K
- 6 December 2012
- Published by Springer Nature in Journal of Solution Chemistry
- Vol. 41 (11) , 1986-1992
Solubility, Dissolution Enthalpy and Entropy of Isoimperatorin in Ethanol + Water Solvent Systems from 288.2 to 328.2 K
- 20 November 2012
- Published by Wiley in Journal of Separation Science
- Vol. 35 (24) , 3469-3476
Analysis and retention behavior of isoflavone glycosides and aglycones in Radix Astragali by HPLC with hydroxypropyl‐β‐cyclodextrin as a mobile phase additive
In order to determine isoflavone glycosides (calycosin‐7‐O‐β‐d‐glucoside and formononetin‐7‐O‐β‐d‐glucoside) and aglycones (calycosin and formononetin), a simple HPLC method with isocratic elution employing hydroxypropyl‐β‐cyclodextrin (HP‐β‐CD) as a mobile phase additive was developed. Various factors affecting the retention of isoflavone glycosides and aglycones in the C18 reversed‐phase column, such as the nature of cyclodextrins, HP‐β‐CD concentration, and methanol concentration, were systematically studied. The results show that HP‐β‐CD, as a very effective mobile phase additive, can markedly reduce the retention of isoflavone glycosides and aglycones, and the decrease magnitudes of isoflavone aglycones are more than those of their glycosides. The role of HP‐β‐CD in the developed HPLC method is attributed to the formation of the inclusion complexes between isoflavone glycosides (or aglycones) and HP‐β‐CD. So, the apparent formation constants of the isoflavone glycosides (or aglycones)/HP‐β‐CD inclusion complexes also were investigated. Isoflavone glycosides (and aglycones) form the 1:1 inclusion complexes with HP‐β‐CD, and the isoflavone aglycones/HP‐β‐CD complexes are more stable than the isoflavone glycosides/HP‐β‐CD complexes. Finally, the optimized method was successfully applied for the determination of isoflavone glycosides and aglycones in Radix Astragali samples.
- 20 November 2012
- Published by Wiley in Journal of Separation Science
- Vol. 35 (24) , 3469-3476
Analysis and retention behavior of isoflavone glycosides and aglycones in Radix Astragali by HPLC with hydroxypropyl‐β‐cyclodextrin as a mobile phase additive
In order to determine isoflavone glycosides (calycosin‐7‐O‐β‐d‐glucoside and formononetin‐7‐O‐β‐d‐glucoside) and aglycones (calycosin and formononetin), a simple HPLC method with isocratic elution employing hydroxypropyl‐β‐cyclodextrin (HP‐β‐CD) as a mobile phase additive was developed. Various factors affecting the retention of isoflavone glycosides and aglycones in the C18 reversed‐phase column, such as the nature of cyclodextrins, HP‐β‐CD concentration, and methanol concentration, were systematically studied. The results show that HP‐β‐CD, as a very effective mobile phase additive, can markedly reduce the retention of isoflavone glycosides and aglycones, and the decrease magnitudes of isoflavone aglycones are more than those of their glycosides. The role of HP‐β‐CD in the developed HPLC method is attributed to the formation of the inclusion complexes between isoflavone glycosides (or aglycones) and HP‐β‐CD. So, the apparent formation constants of the isoflavone glycosides (or aglycones)/HP‐β‐CD inclusion complexes also were investigated. Isoflavone glycosides (and aglycones) form the 1:1 inclusion complexes with HP‐β‐CD, and the isoflavone aglycones/HP‐β‐CD complexes are more stable than the isoflavone glycosides/HP‐β‐CD complexes. Finally, the optimized method was successfully applied for the determination of isoflavone glycosides and aglycones in Radix Astragali samples.